title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Stocks That Hit 52-Week Lows On Wednesday,20220511T162815,https://www.benzinga.com/markets/options/22/05/27141482/52-weeks-high-and-low-article,DSGN,0.006905,Neutral,-0.000891
"Illumina, Seagen And Other Big Stocks Moving Higher On Monday - Agenus  ( NASDAQ:AGEN ) , First Majestic Silver  ( NYSE:AG ) ",20230313T145550,https://www.benzinga.com/news/23/03/31322709/illumina-seagen-and-other-big-stocks-moving-higher-on-monday,DSGN,0.162802,Bullish,0.450092
"Over $5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying - ClearOne  ( NASDAQ:CLRO ) , Carmell Therapeutics  ( NASDAQ:CTCX ) ",20230831T124034,https://www.benzinga.com/trading-ideas/long-ideas/23/08/34142038/over-5m-bet-on-this-healthcare-stock-check-out-these-4-penny-stocks-insiders-are-aggress,DSGN,0.414559,Somewhat-Bullish,0.287339
"MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Cullinan Therapeutics  ( NASDAQ:CGEM ) ",20241226T134928,https://www.benzinga.com/trading-ideas/movers/24/12/42684275/microstrategy-portland-general-electric-and-other-big-stocks-moving-lower-in-thursdays-pre-m,DSGN,0.374312,Bearish,-0.613117
"Nasdaq Falls 100 Points; Siyata Mobile Shares Spike Higher - Design Therapeutics  ( NASDAQ:DSGN ) , Delcath Systems  ( NASDAQ:DCTH ) ",20230815T190408,https://www.benzinga.com/news/earnings/23/08/33865408/nasdaq-falls-100-points-siyata-mobile-shares-spike-higher,DSGN,0.106778,Neutral,0.060546
"Crude Oil Down 2%; Home Depot Posts Upbeat Earnings - Design Therapeutics  ( NASDAQ:DSGN ) , Delcath Systems  ( NASDAQ:DCTH ) ",20230815T160012,https://www.benzinga.com/news/earnings/23/08/33862485/crude-oil-down-2-home-depot-posts-upbeat-earnings,DSGN,0.107255,Neutral,0.060634
"Dow Falls Over 200 Points; US Retail Sales Top Expectations - Design Therapeutics  ( NASDAQ:DSGN ) , Delcath Systems  ( NASDAQ:DCTH ) ",20230815T140139,https://www.benzinga.com/news/earnings/23/08/33859650/dow-falls-over-200-points-us-retail-sales-top-expectations,DSGN,0.120431,Neutral,0.063325
"Why Delcath Systems Shares Are Trading Higher By Around 58%; Here Are 20 Stocks Moving Premarket - Aptevo Therapeutics  ( NASDAQ:APVO ) , Altisource Asset Mgmt  ( AMEX:AAMC ) ",20230815T121728,https://www.benzinga.com/news/23/08/33856601/why-delcath-systems-shares-are-trading-higher-by-around-58-here-are-20-stocks-moving-premarket,DSGN,0.156461,Neutral,-0.111916
"Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Dave  ( NASDAQ:DAVE ) , ARKO  ( NASDAQ:ARKO ) ",20241231T134722,https://www.benzinga.com/24/12/42740288/sangamo-therapeutics-dave-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session,DSGN,0.340915,Neutral,0.0
"Why Cemtrex Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket - Alset  ( NASDAQ:AEI ) , Ambow Education Holding  ( AMEX:AMBO ) ",20241231T103326,https://www.benzinga.com/24/12/42737792/why-cemtrex-shares-are-trading-higher-by-around-17-here-are-20-stocks-moving-premarket,DSGN,0.166743,Neutral,0.0
"Lamb Weston Posts Weak Q2 Results, Joins Micron, Lennar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Akso Health  ( NASDAQ:AHG ) , Abacus Life  ( NASDAQ:ABL ) ",20241219T132922,https://www.benzinga.com/trading-ideas/movers/24/12/42576985/lamb-weston-posts-weak-q2-results-joins-micron-lennar-and-other-big-stocks-moving-lower-in-t,DSGN,0.263942,Neutral,0.0
"Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Aethlon Medical  ( NASDAQ:AEMD ) , Abacus Life  ( NASDAQ:ABL ) ",20241219T111536,https://www.benzinga.com/24/12/42571821/why-sangamo-therapeutics-shares-are-trading-higher-by-around-20-here-are-20-stocks-moving-premarket,DSGN,0.16849,Bearish,-0.447507
NVIDIA Opens BioNeMo to Scale Digital Biology for Global Biopharma and Scientific Industry - NVIDIA  ( NASDAQ:NVDA ) ,20241118T183000,https://www.benzinga.com/pressreleases/24/11/g42045591/nvidia-opens-bionemo-to-scale-digital-biology-for-global-biopharma-and-scientific-industry,DSGN,0.033468,Neutral,0.094682
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences - Design Therapeutics  ( NASDAQ:DSGN ) ,20241113T130049,https://www.benzinga.com/pressreleases/24/11/g41937143/design-therapeutics-to-participate-in-multiple-upcoming-investor-conferences,DSGN,0.535653,Neutral,0.074734
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences,20241113T130000,https://www.globenewswire.com/news-release/2024/11/13/2980244/0/en/Design-Therapeutics-to-Participate-in-Multiple-Upcoming-Investor-Conferences.html,DSGN,0.550532,Neutral,0.079244
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference - Design Therapeutics  ( NASDAQ:DSGN ) ,20240910T120000,https://www.benzinga.com/pressreleases/24/09/g40790539/design-therapeutics-to-participate-in-the-2024-cantor-global-healthcare-conference,DSGN,0.598621,Neutral,0.072621
"Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development - Targeting Inflammatory & Autoimmune Conditions, Obesity And Sexual Dysfunctions - Palatin Techs  ( AMEX:PTN ) ",20240828T125438,https://www.benzinga.com/partner/biotech/24/08/40599753/palatin-technologies-utilizing-the-melanocortin-system-as-the-basis-for-innovation-in-drug-develo,DSGN,0.02379,Neutral,0.062324
Wall Street Analysts Think Design Therapeutics  ( DSGN )  Could Surge 39.72%: Read This Before Placing a Bet,20240821T135506,https://www.zacks.com/stock/news/2325016/wall-street-analysts-think-design-therapeutics-dsgn-could-surge-3972-read-this-before-placing-a-bet,DSGN,0.2842,Bullish,0.366274
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACâ„¢ Portfolio,20240805T120000,https://www.globenewswire.com/news-release/2024/08/05/2924213/0/en/Design-Therapeutics-Announces-Second-Quarter-2024-Financial-Results-and-Reviews-Near-term-Milestones-for-GeneTAC-Portfolio.html,DSGN,0.119532,Neutral,0.0807
"Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying - FTC Solar  ( NASDAQ:FTCI ) , Design Therapeutics  ( NASDAQ:DSGN ) ",20240326T113752,https://www.benzinga.com/trading-ideas/long-ideas/24/03/37930612/design-therapeutics-and-2-other-stocks-under-5-insiders-are-buying,DSGN,0.466325,Somewhat-Bullish,0.268218
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update - Design Therapeutics  ( NASDAQ:DSGN ) ,20240312T103000,https://www.benzinga.com/pressreleases/24/03/g37610931/design-therapeutics-to-webcast-fourth-quarter-and-full-year-2023-financial-results-and-comprehensi,DSGN,0.579393,Neutral,0.081761
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update,20240312T103000,https://www.globenewswire.com/news-release/2024/03/12/2844360/0/en/Design-Therapeutics-to-Webcast-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Comprehensive-Portfolio-Update.html,DSGN,0.504646,Neutral,0.075455
"Design Therapeutics, Inc.  ( DSGN )  Upgraded to Buy: Here's What You Should Know",20231218T170006,https://www.zacks.com/stock/news/2199552/design-therapeutics-inc-dsgn-upgraded-to-buy-heres-what-you-should-know,DSGN,0.359014,Somewhat-Bullish,0.328856
"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN",20231011T193848,https://www.benzinga.com/pressreleases/23/10/g35203040/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-design-therapeu,DSGN,0.419153,Neutral,0.056481
"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN",20231009T230200,https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-design-therapeutics-inc---dsgn-301951325.html,DSGN,0.433523,Somewhat-Bullish,0.180941
"Nested Therapeutics to Present Preclinical Data for Novel, Potential Best-in-Class Inhibitor of the RAS/MAPK Pathway at 2023 AACR-NCI-EORTC Conference",20231004T161500,https://www.prnewswire.com/news-releases/nested-therapeutics-to-present-preclinical-data-for-novel-potential-best-in-class-inhibitor-of-the-rasmapk-pathway-at-2023-aacr-nci-eortc-conference-301947339.html,DSGN,0.113597,Somewhat-Bullish,0.234421
"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN",20230929T225400,https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-design-therapeutics-inc---dsgn-301943499.html,DSGN,0.433523,Somewhat-Bullish,0.180941
"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN",20230926T024907,https://www.benzinga.com/pressreleases/23/09/g34886606/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-design-therapeu,DSGN,0.419153,Neutral,0.056481
"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Design Therapeutics, Inc. - DSGN",20230923T221500,https://markets.businessinsider.com/news/stocks/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-design-therapeutics-inc.-dsgn-1031978478,DSGN,0.416844,Neutral,0.056266
"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN",20230917T225420,https://www.benzinga.com/pressreleases/23/09/g34668118/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-design-therapeu,DSGN,0.419153,Neutral,0.056481
Director At This Health Care Company Buys $14.00M of Stock - Design Therapeutics  ( NASDAQ:DSGN ) ,20230907T150245,https://www.benzinga.com/news/23/09/34323145/director-at-this-health-care-company-buys-14-00m-of-stock,DSGN,0.512093,Somewhat-Bullish,0.292647
"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN",20230901T185451,https://www.benzinga.com/pressreleases/23/09/g34181227/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-design-therapeu,DSGN,0.419153,Neutral,0.056481
"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN",20230828T221100,https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-design-therapeutics-inc---dsgn-301911579.html,DSGN,0.433523,Somewhat-Bullish,0.180941
"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN",20230819T001500,https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-design-therapeutics-inc---dsgn-301904904.html,DSGN,0.433523,Somewhat-Bullish,0.180941
"Design Therapeutics' Modified DT-216 May Have Potential, But Analyst Awaits Further Developments - Design Therapeutics  ( NASDAQ:DSGN ) ",20230815T193235,https://www.benzinga.com/general/biotech/23/08/33862645/design-therapeutics-modified-dt-216-may-have-potential-but-analyst-awaits-further-developments,DSGN,0.485711,Bullish,0.406565
Why Shares of Design Therapeutics Are Plummeting on Tuesday,20230815T190200,https://www.fool.com/investing/2023/08/15/why-shares-of-design-therapeutics-are-plummeting-o/,DSGN,0.25168,Neutral,0.098271
Why Is Design Therapeutics Stock Moving Lower Today? - Design Therapeutics  ( NASDAQ:DSGN ) ,20230815T130454,https://www.benzinga.com/general/biotech/23/08/33855730/why-is-design-therapeutics-stock-moving-lower-today,DSGN,0.42503,Neutral,-0.073691
"Design Therapeutics, Getty Images, Sea Limited And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Kanzhun  ( NASDAQ:BZ ) , Calliditas Therapeutics  ( NASDAQ:CALT ) ",20230815T110026,https://www.benzinga.com/news/23/08/33854726/design-therapeutics-getty-images-sea-limited-and-other-big-stocks-moving-lower-in-tuesdays-pre-marke,DSGN,0.261117,Neutral,-0.043668
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated - Biogen  ( NASDAQ:BIIB ) ,20230728T155617,https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33444357/reatas-acquisition-fits-biogens-strategy-despite-high-cost-analyst-says-high-level-,DSGN,0.280615,Neutral,0.0
"Why American Equity Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - American Equity Inv  ( NYSE:AEL ) , Adicet Bio  ( NASDAQ:ACET ) ",20230627T121937,https://www.benzinga.com/news/23/06/33021667/why-american-equity-are-trading-higher-by-around-9-here-are-20-stocks-moving-premarket,DSGN,0.12645,Neutral,0.0
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference,20230531T103000,https://www.globenewswire.com/news-release/2023/05/31/2679170/0/en/Design-Therapeutics-to-Present-at-the-2023-Jefferies-Healthcare-Conference.html,DSGN,0.495015,Neutral,-0.068652
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference - Design Therapeutics  ( NASDAQ:DSGN ) ,20230531T103000,https://www.benzinga.com/pressreleases/23/05/g32642653/design-therapeutics-to-present-at-the-2023-jefferies-healthcare-conference,DSGN,0.323078,Neutral,-0.063531
"Design Therapeutics to Present Preclinical Data on its GeneTACâ„¢ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023 - Design Therapeutics  ( NASDAQ:DSGN ) ",20230424T103000,https://www.benzinga.com/pressreleases/23/04/g31952395/design-therapeutics-to-present-preclinical-data-on-its-genetac-small-molecule-dt-168-for-the-treat,DSGN,0.06623,Neutral,0.010037
"Design Therapeutics to Present Preclinical Data on its GeneTACâ„¢ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023",20230424T103000,https://www.globenewswire.com/news-release/2023/04/24/2652505/0/en/Design-Therapeutics-to-Present-Preclinical-Data-on-its-GeneTAC-Small-Molecule-DT-168-for-the-Treatment-of-Fuchs-Endothelial-Corneal-Dystrophy-at-ARVO-2023.html,DSGN,0.101725,Neutral,-0.008641
"First Republic Bank, Blend Labs, Purple Innovation And Other Big Stocks Moving Lower On Friday - Aspen Aerogels  ( NYSE:ASPN ) , Blend Labs  ( NYSE:BLND ) ",20230317T155529,https://www.benzinga.com/news/23/03/31400166/first-republic-bank-blend-labs-purple-innovation-and-other-big-stocks-moving-lower-on-friday,DSGN,0.219809,Neutral,0.0
OpenAI's 37-year-old CEO bet $180 million on a little-known biotech startup that's trying to help people live 10 years longer,20230309T134807,https://africa.businessinsider.com/science/openais-37-year-old-ceo-bet-dollar180-million-on-a-little-known-biotech-startup-thats/e7s4s6h,DSGN,0.090816,Somewhat-Bullish,0.209783
OpenAI's 37-year-old CEO bet $180 million on a little-known biotech startup that's trying to help people live 10 years longer,20230309T134807,https://www.businessinsider.com/openai-ceo-sam-altman-investment-longevity-startup-retro-2023-3,DSGN,0.079392,Somewhat-Bullish,0.204361
Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference,20230208T113000,https://www.globenewswire.com/news-release/2023/02/08/2603742/0/en/Design-Therapeutics-to-Participate-in-the-SVB-Securities-Virtual-Global-Biopharma-Conference.html,DSGN,0.468029,Neutral,-0.027238
Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference - Design Therapeutics  ( NASDAQ:DSGN ) ,20230208T113000,https://www.benzinga.com/pressreleases/23/02/g30803612/design-therapeutics-to-participate-in-the-svb-securities-virtual-global-biopharma-conference,DSGN,0.305058,Neutral,0.032955
"DESIGN ALERT: Bragar Eagel & Squire, P.C. is Investigating Design Therapeutics, Inc. on Behalf of Design Stockholders and Encourages Investors to Contact the Firm - Design Therapeutics  ( NASDAQ:DSGN ) ",20221231T020100,https://www.benzinga.com/pressreleases/22/12/g30244082/design-alert-bragar-eagel-squire-p-c-is-investigating-design-therapeutics-inc-on-behalf-of-design-,DSGN,0.25168,Neutral,-0.107257
"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN",20221225T015842,https://www.benzinga.com/pressreleases/22/12/g30195737/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-design-therapeu,DSGN,0.280615,Neutral,0.0
"MillerKnoll, Cleveland-Cliffs And Some Other Big Stocks Moving Higher On Thursday - AMC Entertainment  ( NYSE:AMC ) , Alvotech  ( NASDAQ:ALVO ) ",20221222T155706,https://www.benzinga.com/news/22/12/30175977/millerknoll-cleveland-cliffs-and-some-other-big-stocks-moving-higher-on-thursday,DSGN,0.388879,Bullish,0.729309
"Complementary and Alternative Medicine Market to Experience Substantial Growth of USD 477.29 Billion by 2029, Size, Share, Growth Rate, Demand, Opportunities and Competitive Landscape",20221222T111500,https://www.prnewswire.com/news-releases/complementary-and-alternative-medicine-market-to-experience-substantial-growth-of-usd-477-29-billion-by-2029--size-share-growth-rate-demand-opportunities-and-competitive-landscape-301708943.html,DSGN,0.019317,Neutral,0.045747
"$7.5 Million Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying - Design Therapeutics  ( NASDAQ:DSGN ) , Flowers Foods  ( NYSE:FLO ) ",20221221T112538,https://www.benzinga.com/trading-ideas/long-ideas/22/12/30157559/7-5-million-bet-on-this-biotechnology-stock-check-out-these-3-stocks-insiders-are-buying,DSGN,0.495015,Somewhat-Bullish,0.310282
"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN",20221208T212734,https://www.benzinga.com/pressreleases/22/12/g30014950/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-design-therapeu,DSGN,0.280615,Neutral,0.0
"S&P 500 Rises 0.5%; Ciena Posts Upbeat Q4 Results - Ciena  ( NYSE:CIEN ) , Agora  ( NASDAQ:API ) ",20221208T194133,https://www.benzinga.com/news/22/12/30013286/s-p-500-rises-0-5-ciena-posts-upbeat-q4-results,DSGN,0.13347,Neutral,0.046431
"Nasdaq Gains 100 Points; Rent the Runway Shares Spike Higher - Ciena  ( NYSE:CIEN ) , Agora  ( NASDAQ:API ) ",20221208T171209,https://www.benzinga.com/news/earnings/22/12/30011050/nasdaq-gains-100-points-rent-the-runway-shares-spike-higher,DSGN,0.143415,Neutral,0.048339
"Chefs' Warehouse, Chart Industries And Some Other Big Stocks Moving Lower On Thursday - Cano Health  ( NYSE:CANO ) , The Chefs' Warehouse  ( NASDAQ:CHEF ) ",20221208T160409,https://www.benzinga.com/news/22/12/30009897/chefs-warehouse-chart-industries-and-some-other-big-stocks-moving-lower-on-thursday,DSGN,0.290607,Somewhat-Bullish,0.328831
"Dow Rises 150 Points; US Jobless Claims Increase To 230,000 - Ciena  ( NYSE:CIEN ) , Ardmore Shipping  ( NYSE:ASC ) ",20221208T150324,https://www.benzinga.com/news/earnings/22/12/30008363/dow-rises-150-points-us-jobless-claims-increase-to-230-000,DSGN,0.155451,Neutral,0.050792
"Foot Locker, Ross Stores, Palo Alto Networks, And Other Big Gainers From Friday - Ambarella  ( NASDAQ:AMBA ) , Apellis Pharmaceuticals  ( NASDAQ:APLS ) ",20221121T093732,https://www.benzinga.com/news/22/11/29799908/foot-locker-ross-stores-palo-alto-networks-and-other-big-gainers-from-friday,DSGN,0.187705,Neutral,-0.007936
"Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTACâ„¢ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022 - Design Therapeutics  ( NASDAQ:DSGN ) ",20221017T200500,https://www.benzinga.com/pressreleases/22/10/g29295735/design-therapeutics-to-present-preclinical-data-highlighting-the-potential-of-its-genetac-small-mo,DSGN,0.072987,Neutral,0.01007
Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit,20220922T103000,https://www.globenewswire.com/news-release/2022/09/22/2520831/0/en/Design-Therapeutics-to-Present-at-the-2022-Jefferies-Cell-and-Genetic-Medicine-Summit.html,DSGN,0.546745,Neutral,0.092309
Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit - Design Therapeutics  ( NASDAQ:DSGN ) ,20220922T103000,https://www.benzinga.com/pressreleases/22/09/g28960870/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit,DSGN,0.358152,Neutral,-0.046706
Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference,20220803T103000,https://www.globenewswire.com/news-release/2022/08/03/2491131/0/en/Design-Therapeutics-to-Participate-in-the-2022-Wedbush-PacGrow-Virtual-Healthcare-Conference.html,DSGN,0.546745,Neutral,0.095612
Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference,20220803T103000,https://www.benzinga.com/pressreleases/22/08/g28326477/design-therapeutics-to-participate-in-the-2022-wedbush-pacgrow-virtual-healthcare-conference,DSGN,0.358152,Neutral,-0.051624
Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference,20220601T103000,https://www.globenewswire.com/news-release/2022/06/01/2454005/0/en/Design-Therapeutics-to-Present-at-the-2022-Jefferies-Healthcare-Conference.html,DSGN,0.548255,Neutral,0.013844
Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference,20220601T103000,https://www.benzinga.com/pressreleases/22/06/g27493362/design-therapeutics-to-present-at-the-2022-jefferies-healthcare-conference,DSGN,0.355333,Neutral,0.001167
Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTACâ„¢ Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022,20220309T113000,https://www.globenewswire.com/news-release/2022/03/09/2399737/0/en/Design-Therapeutics-Announces-Preclinical-Data-Highlighting-Novel-GeneTAC-Therapy-for-the-Treatment-of-Fuchs-Endothelial-Corneal-Dystrophy-to-be-Presented-at-ARVO-2022.html,DSGN,0.227966,Neutral,0.025373
Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTACâ„¢ Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022,20220309T113000,https://www.benzinga.com/pressreleases/22/03/g26056631/design-therapeutics-announces-preclinical-data-highlighting-novel-genetac-therapy-for-the-treatmen,DSGN,0.214652,Neutral,0.036066
